Oxford Biotheraputics
Board of Directors
Board of Directors
  • Bernd Seizinger, M.D., Ph.D



    Bernd Seizinger has held a number of senior executive and board positions in both U.S. and European biotech and pharmaceutical companies (public and private) including: President & CEO of GPC Biotech (Germany/ U.S.); VP Oncology Drug Discovery & Molecular Genetics, and – in parallel- VP Corporate and Academic Alliances at Bristol-Myers-Squibb (U.S.); EVP/CSO of Genome Therapeutics (U.S.); CEO/Chairman of CryptoMedix (U.S.); Executive Chairman/Chairman of Aprea (Sweden/U.S.); Executive/Chairman of Opsona (Ireland), and multiple additional board appointments in biotech and pharma companies on both sides of the Atlantic.

    Prior to his corporate appointments, Dr Seizinger held senior faculty positions at Harvard Medical School and Massachusetts General Hospital, and was a Visiting Professor at Princeton University during his tenure at Bristol-Myers Squibb.

    He has authored more than 100 scientific publications – including multiple papers in Nature, Science and Cell – and has been the recipient of numerous scientific awards.

  • Christian Rohlff, PhD

    Chief Executive Officer


    Dr Rohlff has approximately 20 years’ commercial, business development and intellectual property experience gained in the international biotechnology industry. He became Chief Executive of Oxford BioTherapeutics in 2004, after founding the company and acquiring targeting technology, bioinformatics data and intellectual property from Oxford GlycoSciences, following its acquisition by Celltech. Prior to this, as Director of Oxford GlycoSciences’ proteomics collaborations, he led the company’s partnerships in oncology and other serious diseases with leading pharmaceutical companies and institutions, including Pfizer, GSK, Bayer, Wyeth, Takeda, the Cystic Fibrosis Foundation, Oxford University and the FDA. Previously, he held a number of positions at the US National Cancer Institute. Dr Rohlff holds a PhD from the Department of Pharmacology at Georgetown University.

  • Jean-Pierre Bizzari, M.D.

    Non-Executive Director


    Dr Bizzari has held a number of senior executive positions within the pharmaceutical industry. He started his career as Head of the Oncology at the Institut de Recherches Internationales SERVIER (France), followed by a move to Rhone-Poulenc Rorer where he was Vice President of Clinical Oncology, based in Paris, and subsequently responsible for Oncology Clinical Development at Aventis as Vice President. He was previously Vice President of Clinical Development, Oncology, of Sanofi-Aventis in Malvern, before moving to Celgene as Executive Vice President, Clinical Development Oncology.

    Dr Bizzari has been involved in the development of numerous compounds such as anti-angiogenics (VEGF-trap), gene therapy, vaccines and bio-reductive agents. He is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa), and a board member of the European Organisation of Research and Treatment of Cancer (EORTC). In addition, he sits on the Board of a number of corporate organisations. He has published more than 70 articles in peer review journals and more than 160 abstracts in scientific congresses. Dr Bizzari was also instrumental in the clinical development of several anticancer agents including Taxotere, Revlimid, and Vidaza.

    Dr Bizzari holds a medical degree from the University of Nice (France) and trained as an oncologist at the Pitie Salpetriere hospital in Paris. He trained at the Ontario Cancer Institute and Mac Gill Cancer Centre, Canada.

  • Shawn Tomasello, MBA

    Non-Executive Director


    Shawn Cline Tomasello has over 30 years of experience in pharmaceutical and biotech industries, most recently, as the Chief Commercial Officer at Pharmacyclics where she led the commercial and medical affairs teams. While at Pharmacyclics as an officer and member of the executive team, the market cap increased significantly, resulting in an acquisition by AbbVie for $21 billion. Ms. Tomasello has extensive strategic experience in building world class organizations.

    Ms. Tomasello is the former President of the Americas, Hematology and Oncology, for Celgene Corporation where she was responsible for all aspects of the commercial organization. In addition, she was instrumental in global strategic decision making regarding global expansion and M&A evaluations.

    Prior to joining Celgene, Ms. Tomasello was at Genetech for 16 years in various roles, including, National Director of Hematology for Rituxan. Earlier in her career, she held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble.

    Ms. Tomasello received her B.S. in Marketing from the University of Cincinnati and her M.B.A. from Murray State University, Kentucky. She has served on the board of BIONJ and has been a member of the advisory board for Healthcare Businesswomen’s Association (HBA).

  • Tom Bradley

    Non-Executive Director


    Tom Bradley leads the growth capital team at Oxford Capital with responsibility for all investment and portfolio activities. He has over 15 years of venture and growth capital experience.

    Prior to Oxford Capital, Tom was a Partner at DN Capital, a leading early stage software and internet investor with offices in London and Menlo Park. While at DN Capital he led investments in companies such as Performance Horizon Group, Airsense Wireless,, Lovespace, and Mister Spex. Tom also worked closely with leading businesses such as Shazam and

    Earlier in his career Tom was a Founder Partner of DFJ Esprit as part of the team that spun out of Cazenove. During that time he was instrumental in investments such as LOVEFILM (sold to Amazon) and Neteconomy (sold to Fiserv). He spent his early career at SOFTBANK Capital and Datamonitor. Tom holds an MA in Modern History from Oxford University where he studied at Brasenose College.